Cytoskeletal Tropomyosin as a Biomarker in Clostridium difficile Infection

Area of Science:

• Microbiology
• Clinical Diagnostics
• Biomarker Discovery

Background:

• Current Clostridium difficile infection (CDI) diagnostics primarily detect the organism.
• Investigating tropomyosin (Tpm), a cytoskeletal protein, as a novel CDI biomarker.

Purpose of the Study:

• To evaluate the diagnostic utility of fecal Tpm for Clostridium difficile infection (CDI).
• To assess the sensitivity and specificity of Tpm detection in stool specimens.

Main Methods:

• A prospective study analyzed 510 fecal specimens using monoclonal antibodies against Tpm.
• Samples were categorized as CDI positive (PCR-based) or negative, with an additional group for other enteric pathogens.
• Fecal Tpm levels were measured by Western blot and correlated with clinical and microbiological data.

Main Results:

• Tropomyosin (Tpm) stability in stool is limited, highlighting the need for fresh specimens.
• Tpm detection showed 93.2% specificity and 53.7% sensitivity for CDI.
• A subset of CDI positive samples (23%) lacked typical clinical signs, and Tpm positives in the CDI negative group (8.3%) had inflammatory bowel diseases.

Conclusions:

• Tropomyosin (Tpm) may serve as a supplementary biomarker for CDI when used with PCR and clinical assessment.
• Non-muscle Tpm demonstrated low sensitivity as a CDI biomarker in this study.
• Larger cohort studies are necessary to further validate Tpm's role in CDI diagnostics.